Nicola Ferri
 | Department of Pharmaceutical and Pharmacological Sciences, University of Padova Position: Associate Professor Contacts |
Short CV
PERSONAL DATA
Date of birth: October 25, 1971
Place of birth: Mede Lomellina (PV), Italy Nationality: Italian
Mailing address: Department of Pharmaceutical Sciences, University of Padua, Largo Egidio Meneghetti 2, 35131 Padua, Italy
EDUCATION
1990 Student in Pharmaceutical Chemistry and Technology, University of Milan, Italy
1996 Doctor in Pharmaceutical Chemistry and Technology, "Magna cum Laude", University of Milan, Italy
1998 Ph.D. in “Experimental Pharmacology” at the University of Milan, Italy
2002 Ph.D. in "Toxicology of Environment and Nutrition" at the University of Milan, Italy
2006 Master in “Pharmacy and Oncological Pharmacology” at the University of Milan, Italy
RESEARCH EXPERIENCE
Since 2018 Associate Professor, Department of Pharmaceutical Science, University of Padua, Padua, Italy
2015-2018 Research Assistant Professor (RTD B), Department of Pharmaceutical Science, University of Padua, Padua, Italy
2014–2015 Research Assistant Professor (RTD A), Department of Biomolecular and Pharmacological Sciences, University of Milan, Italy
2003-2014 Post-Doctoral position at the University of Milan, Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy
2004 "Visiting Scientist" (2 months) at the University of Washington (Seattle, USA) in the laboratory directed by Elaine Raines
1999-2003 "Senior Research Fellow" at the Department of Pathology, School of Medicine, University of Washington, Seattle, WA, USA in the Laboratory directed by Dr. Russell Ross and Prof. Elaine W. Raines
1999-2002 Doctoral Research in the laboratory directed by Prof. Remo Fumagalli, Institute of Pharmacological Sciences, University of Milan
1997-1999 Doctoral Research in the laboratory directed by Prof. Remo Fumagalli, Institute of Pharmacological Sciences, University of Milan
HONORS, SCOLARSHIPS, FELLOWSHIPS
1996-1998 Winner of a fellowship disposed by Pharmaceutical Company Tecnofarmaci S.C.p.A. Rome Italy.
1998-2002 Winner of a fellowship from Ph.D. school of Toxicology of Environment and Alimentation at the University of Milan
2003 Winner of scientific award "Giovanni Galli" at University of Milan, supported by Italian Society for the study of atherosclerosis (SISA).
2006 "Young Investigator Poster Award, Honorable Mention" at the XIV International Symposium of Atherosclerosis, Roma (Italia).
2006 Winner of the ward “Giovani Ricercatori” at University of Milan, supported by Italian Society for the study of atherosclerosis (SISA).
2007 Winner of Travel Grant SISA for the XXI National Congress of Italian Society for the study of atherosclerosis (SISA), Perugia (ITALY).
2008 Winner of the award “Giovani Ricercatori” supported by Italian Society for the study of atherosclerosis (SISA), Milan, ITALY.
2013 Winner of Travel Grant SISA for the XXVII National Congress of Italian Society for the study of atherosclerosis (SISA), Rome (ITALY).
Teaching
Office hours
Every day upon appointment
Availability for Thesis Projects
Cardiovascular Pharmacology.
Research
Technical expertise
In vitro experimental pharmacology assay (cellular and molecular biology)
In vivo model of atherosclerosis (vascular restenosis)
Positions available
None
Publications
1. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Ruscica M, Simonelli S, Botta M, Ossoli A, Lupo MG, Magni P, Corsini A, Arca M, Pisciotta L, Veglia F, Franceschini G, Ferri N, Calabresi L. Biochim Biophys Acta. 2018 May 29; 1863: 991-997. doi: 10.1016/j.bbalip.2018.05.015.
2. PCSK9 as a Positive Modulator of Platelet Activation. Camera M, Rossetti L, Barbieri SS, Zanotti I, Canciani B, Trabattoni D, Ruscica M, Tremoli E, Ferri N. J Am Coll Cardiol. 2018;71: 952-954. doi: 10.1016/j.jacc.2017.11.069.
3. PCSK9 induces a pro-inflammatory response in macrophages. Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, Fogacci F, Corsini A, Ferri N. Sci Rep. 2018 Feb 2;8(1):2267. doi: 10.1038/s41598-018-20425-x.
4. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Ferri N, Marchianò S, Tibolla G, Baetta R, Dhyani A, Ruscica M, Uboldi P, Catapano A.L., Corsini A. Atherosclerosis. 2016; 253: 214-224. doi: 10.1016/j.atherosclerosis.2016.07.910
5. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic hepg2 cell line. Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, E Ferri N. J Biol Chem. 2016; 291: 3508-19. doi: 10.1074/jbc.M115.664706
Patents
1) European Patent Application: EP 2 241 555 A1: New Rac1 Inhibitors As Potential Pharmacological Agents For Heart Failure Treatment
2) International Patent Application: WO 2010/119050 A1: New Rac1 Inhibitors As Potential Pharmacological Agents For Heart Failure Treatment
Research projects and Funds
2000- Principal Investigator of the research program “Potential role of new collagen receptors (DDR1 and DDR2) in Smooth Muscle Growth in LAM” (LAM Foundation, Cincinnati OH, USA).
2016-Principal Investigator of the research program “Investigating the relationship between PCSK9 and chronic inflammation associated with obesity and insulin resistance” (PRID, Università degli Studi di Padova, Dipartimento di Scienze del Farmaco)
2016- Principal Investigator of the research program “Studio dell’efficacia di una nuova formulazione, TRIO, a base di vitamina K2 (MK-7), carbonato di magnesio e pirofosfato ferrico (ferro sucrosomiale, Pharmanutra spa) per la prevenzione delle calcificazioni arteriose in un modello animale di insufficienza renale” (Pharmanutra)
2016- Research Unit Coordinator of the research program “PCSK9 in human platelets: assessment of the role and implications for platelet activation in patients with cardiovascular disease and diabetes”. ASPIRE Cardiovascular Competitive Research Grants Program 2016
2018- Research Unit Coordinator of the research program “Exploring the pathophysological role of PCSK9 in Alzheimer’s disease: focus on inflammation and lipid metabolism (exit-ad)” AMGEN competitive grant program.
2019- Research Unit Coordinator of the research program PRIN 2017 “Low density lipoprotein receptor (LDLR)-independent effects of proprotein convertase subtilisin/kexin type 9 (PCSK9): role in modulating insulin-resistance, ectopic fat accumulation and low-grade inflammation
